FDA Says Popular ‘Weight Loss Meds’ No Longer in Shortage: What Patients Need to Know

Resources for the Community:___________________________________________________________________Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55https://a4pc.org/find-a-compounder/If You are having issues accessing Paid Subscriber content please send an email to [email protected] and a member of Buzzsprout's technical team will help you access the content._____________________________________________________________________In this timely bonus episode of The Plus SideZ Podcast, we dive into the FDA’s decision to end the tirzepatide shortage, its 60-90 day grace period for compounding pharmacies, and what this means for patients relying on affordable access to GLP-1 medications like Zepbound and Mounjaro. Joining us is Scott Brunner, CEO of the Alliance for Pharmacy Compounding, to discuss the impact of this ruling, safety concerns, and the role of compounded medications in obesity care.We also explore the new PBM reform bill, aiming to address access and affordability challenges for patients. Whether you’re a patient, provider, or advocate, this episode unpacks the critical issues shaping the future of obesity and diabetes treatments.Tune in to learn how to navigate these changes and make informed decisions for your health. #GLP1 #Tirzepatide #ObesityCare #PBMReform______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Send us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram